Anti-Amyloid Oligomers抗体
Anti-Amyloid Oligomers antibody
4
(2 Reviews)
|
(11 Publications)
Rabbit Polyclonal Amyloid-beta precursor protein antibody. Suitable for IP, ELISA, Dot, WB, IHC-P, IHC-Fr and reacts with Mouse, Rat, Human samples. Cited in 11 publications.
查看别名
A4, AD1, APP, Amyloid-beta precursor protein, ABPP, APPI, Alzheimer disease amyloid A4 protein homolog, Alzheimer disease amyloid protein, Amyloid precursor protein, Amyloid-beta (A4) precursor protein, Amyloid-beta A4 protein, Cerebral vascular amyloid peptide, PreA4, Protease nexin-II, CVAP, PN-II
反应性数据
性能和储存信息
形式
纯化工艺
存储溶液
运输条件
推荐的短期储存条件
推荐的长期储存条件
储存信息
补充信息
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
Amyloid oligomers interfere with synaptic function leading to a cascade of neuronal dysfunction and cell death. Unlike their fibrillar counterparts these oligomers are not part of larger insoluble plaques and they exhibit more harmful properties to neurons. They may form part of a complex with other proteins such as tau which can exacerbate their toxic effects. Amyloid beta oligomers disrupt cellular function primarily through interaction with synaptic receptors influencing calcium homeostasis and promoting oxidative stress.
Pathways
Amyloid oligomers are integral components of amyloidogenic pathways that influence neuronal communication and survival. The amyloid beta pathway involves the cleavage of amyloid precursor protein (APP) by enzymes such as beta-secretase and gamma-secretase leading to the formation of these toxic oligomers. Related proteins include APP the enzymes mentioned and tau which can further disrupt microtubule stability when amyloid oligomers are present. The accumulation of amyloid oligomers is interlinked with pathways that regulate synaptic plasticity and inflammatory responses.
产品实验方案
- Visit the General protocols
- Visit the Troubleshooting
靶点信息
文献 (11)
Recent publications for all applications. Explore the full list and refine your search
The Journal of clinical investigation : PubMed41026542
2025
Applications
Unspecified application
Species
Unspecified reactive species
Scientific reports 15:4393 PubMed39910105
2025
Applications
Unspecified application
Species
Unspecified reactive species
Alzheimer's & dementia : the journal of the Alzheimer's Association 20:6094-6106 PubMed38958575
2024
Applications
Unspecified application
Species
Unspecified reactive species
Scientific reports 11:8617 PubMed33883656
2021
Applications
Unspecified application
Species
Unspecified reactive species
PloS one 15:e0237667 PubMed32833960
2020
Applications
Unspecified application
Species
Unspecified reactive species
Scientific reports 10:7103 PubMed32345996
2020
Applications
Unspecified application
Species
Unspecified reactive species
Scientific reports 9:18465 PubMed31804529
2019
Applications
Unspecified application
Species
Unspecified reactive species
FEBS letters 593:2139-2150 PubMed31211853
2019
Applications
Unspecified application
Species
Unspecified reactive species
Journal of neuroscience research 97:492-505 PubMed30461032
2018
Applications
Unspecified application
Species
Unspecified reactive species
Cell reports 24:1713-1721.e4 PubMed30110628
2018
Applications
Unspecified application
Species
Unspecified reactive species
Abcam Product Promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com